RDY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dr. Reddy's Laboratories Ltd is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has weak financial performance, negative analyst sentiment, and no significant positive catalysts. Additionally, technical indicators and options data do not suggest a strong entry point.
The MACD is slightly positive (0.0321) and expanding, but RSI (65.091) is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 13.648), indicating limited upside potential.
No significant positive catalysts identified. Recent news and trading trends are neutral.
Goldman Sachs and Citi have downgraded the stock to Sell, citing limited pipeline opportunities and intense competition for generic Ozempic in Canada. Financial performance has declined across key metrics, including revenue (-1.02% YoY), net income (-18.84% YoY), and EPS (-20.00% YoY).
In Q3 2026, revenue dropped to 979798055.4 (-1.02% YoY), net income dropped to 135829821.63 (-18.84% YoY), EPS dropped to 0.16 (-20.00% YoY), and gross margin dropped to 53.63 (-8.61% YoY).
Goldman Sachs downgraded the stock to Sell with a price target of INR 1,075, citing concerns about the generic Ozempic opportunity and a limited drug pipeline. Citi reiterated a Sell rating, noting that the market for generic semaglutide in Canada is overcrowded and the rally overstates potential upside.
